Putzki Norman, Katsarava Zaza, Vago Susanne, Diener H C, Limmroth Volker
Department of Neurology, University Hospital Essen, Essen, Germany.
Eur Neurol. 2008;59(3-4):136-42. doi: 10.1159/000111876. Epub 2007 Nov 30.
Fatigue is one of the most frequent and most disabling symptoms in multiple sclerosis (MS). We investigated the possible association of the MS-related fatigue syndrome with the available disease-modifying therapies and the main disease characteristics in a cross-sectional study on 320 consecutive patients. The prevalence of severe fatigue (Fatigue Severity Scale score > or =5) was 50%. In a multivariate regression model controlling for age, disease subtype, duration and disability we did not find a significant association between the use of immunosuppressive or immunomodulatory drugs compared to no treatment (OR = 1.34, p = 0.38 for immunosuppressants; OR = 0.95, p = 0.85 for immune-modulating agents). Although all used disease-modifying agents successfully reduce disease activity and inflammation, they do not appear to exhibit a significant effect on MS-related fatigue.
疲劳是多发性硬化症（MS）中最常见且最具致残性的症状之一。在一项对320例连续患者的横断面研究中，我们调查了MS相关疲劳综合征与现有疾病修饰疗法以及主要疾病特征之间的可能关联。严重疲劳（疲劳严重程度量表评分≥5）的患病率为50%。在控制年龄、疾病亚型、病程和残疾程度的多变量回归模型中，我们发现与未治疗相比，使用免疫抑制或免疫调节药物之间没有显著关联（免疫抑制剂的OR = 1.34，p = 0.38；免疫调节剂的OR = 0.95，p = 0.85）。尽管所有使用的疾病修饰药物都成功降低了疾病活动度和炎症，但它们似乎对MS相关疲劳没有显著影响。
